A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | MicrobiomeTrials
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-03-12Est. Completion: 2026-03-10
Enrollment target: 555 participants
Locations
SB Investigative Site, Banja Luka, Bosnia and Herzegovina
SB Investigative Site, Mostar, Bosnia and Herzegovina
SB Investigative Site, Sarajevo, Bosnia and Herzegovina
SB Investigative Site, Curitiba, Brazil
SB Investigative Site, Florianópolis, Brazil
SB Investigative Site, Ijuí, Brazil
SB Investigative Site, Natal, Brazil
SB Investigative Site, Pelotas, Brazil
SB Investigative Site 1, Porto Alegre, Brazil
SB Investigative Site 2, Porto Alegre, Brazil
SB Investigative Site, Rio de Janeiro, Brazil
SB Investigative Site, Santo André, Brazil
SB Investigative Site, Batumi, Georgia
SB Investigative Site 1, Tbilisi, Georgia
SB Investigative Site 2, Tbilisi, Georgia
SB Investigative Site 3, Tbilisi, Georgia
SB Investigative Site 4, Tbilisi, Georgia
SB Investigative Site 5, Tbilisi, Georgia
SB Investigative Site 6, Tbilisi, Georgia
Other microbiome trials you might be interested in